De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Byhealth Toekomstige groei

Future criteriumcontroles 1/6

Byhealth zal naar verwachting groeien in winst en omzet met respectievelijk 19.6% en 8.9% per jaar. De winst per aandeel zal naar verwachting groeien met 19.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.9% zijn.

Belangrijke informatie

19.6%

Groei van de winst

19.6%

Groei van de winst per aandeel

Personal Products winstgroei	21.1%
Inkomstengroei	8.9%
Toekomstig rendement op eigen vermogen	12.9%
Dekking van analisten	Good
Laatst bijgewerkt	30 Sep 2024

Recente toekomstige groei-updates

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 23

Recent updates

Byhealth Co., Ltd (SZSE:300146) Surges 32% Yet Its Low P/E Is No Reason For Excitement

Sep 30

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 23

Winst- en omzetgroeiprognoses

SZSE:300146 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	10,354	1,749	1,466	1,774	9
12/31/2025	9,425	1,513	764	1,627	10
12/31/2024	8,428	1,188	-467	1,255	9
6/30/2024	8,424	1,092	995	1,306	N/A
3/31/2024	8,945	1,443	223	1,535	N/A
12/31/2023	9,407	1,746	794	2,051	N/A
9/30/2023	9,484	1,805	666	1,938	N/A
6/30/2023	9,237	1,883	818	2,075	N/A
3/31/2023	8,689	1,752	1,833	2,090	N/A
12/31/2022	7,861	1,386	1,134	1,379	N/A
9/30/2022	7,563	1,573	1,404	1,645	N/A
6/30/2022	7,454	1,431	1,170	1,430	N/A
3/31/2022	7,489	1,601	1,468	1,721	N/A
12/31/2021	7,431	1,754	1,556	1,819	N/A
9/30/2021	7,091	1,720	1,000	1,267	N/A
6/30/2021	7,168	1,934	1,299	1,534	N/A
3/31/2021	6,822	1,806	1,236	1,573	N/A
12/31/2020	6,095	1,524	1,245	1,566	N/A
9/30/2020	5,914	-80	1,733	2,039	N/A
6/30/2020	5,417	-261	1,485	1,821	N/A
3/31/2020	5,186	-319	1,319	1,576	N/A
12/31/2019	5,262	-356	1,205	1,537	N/A
9/30/2019	5,310	1,132	880	1,192	N/A
6/30/2019	5,151	1,161	974	1,238	N/A
3/31/2019	4,854	1,125	905	1,234	N/A
12/31/2018	4,351	999	1,098	1,349	N/A
9/30/2018	4,182	1,018	968	1,226	N/A
6/30/2018	3,794	885	827	1,084	N/A
3/31/2018	3,442	852	N/A	951	N/A
12/31/2017	3,111	763	N/A	954	N/A
9/30/2017	2,747	771	N/A	809	N/A
6/30/2017	2,562	759	N/A	772	N/A
3/31/2017	2,389	594	N/A	694	N/A
12/31/2016	2,309	535	N/A	685	N/A
9/30/2016	2,398	619	N/A	710	N/A
6/30/2016	2,322	577	N/A	583	N/A
3/31/2016	2,344	655	N/A	613	N/A
12/31/2015	2,266	635	N/A	635	N/A
9/30/2015	2,101	609	N/A	606	N/A
6/30/2015	1,944	566	N/A	624	N/A
3/31/2015	1,806	530	N/A	572	N/A
12/31/2014	1,705	503	N/A	561	N/A
9/30/2014	1,704	547	N/A	674	N/A
6/30/2014	1,668	542	N/A	764	N/A
3/31/2014	1,594	481	N/A	707	N/A
12/31/2013	1,482	422	N/A	627	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300146 ( 19.6% per jaar) ligt boven de spaarquote ( 2.9% ).

Winst versus markt: De winst van 300146 ( 19.6% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 23.2% per jaar).

Hoge groeiwinsten: De winst van 300146 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 300146 ( 8.9% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.2% per jaar).

Hoge groei-inkomsten: De omzet van 300146 ( 8.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300146 zal naar verwachting over 3 jaar laag zijn ( 12.9 %).

Byhealth Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 18%

Price target decreased by 10% to CN¥19.91

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 8.9% to CN¥24.05

Price target decreased by 7.7% to CN¥26.37

Price target increased to CN¥27.71

Recent updates

Byhealth Co., Ltd (SZSE:300146) Surges 32% Yet Its Low P/E Is No Reason For Excitement

Byhealth Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 17%

Byhealth (SZSE:300146) Will Want To Turn Around Its Return Trends

Consensus revenue estimates fall by 18%

Things Look Grim For Byhealth Co., Ltd (SZSE:300146) After Today's Downgrade

Price target decreased by 10% to CN¥19.91

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.095 (vs CN¥0.30 in 2Q 2023)

Investors Don't See Light At End Of Byhealth Co., Ltd's (SZSE:300146) Tunnel

Byhealth Co., Ltd to Report First Half, 2024 Results on Aug 06, 2024

Byhealth (SZSE:300146) Could Be Struggling To Allocate Capital

First quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.61 in 1Q 2023)

Byhealth Co., Ltd Approves Cash Dividend for the Year 2023

Byhealth Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

We Think That There Are Issues Underlying Byhealth's (SZSE:300146) Earnings

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Byhealth Co., Ltd Announces Profit Distribution Proposal for 2023

Byhealth Co., Ltd, Annual General Meeting, Apr 11, 2024

Price target decreased by 8.9% to CN¥24.05

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.82 in FY 2022)

Now 21% overvalued

Byhealth Co., Ltd to Report Fiscal Year 2023 Results on Mar 19, 2024

Price target decreased by 7.7% to CN¥26.37

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.25 in 3Q 2022)

Provexis plc Announces Byhealth Co., Ltd Regulatory Filing with Chinese SAMR

High number of new directors

Byhealth Co. Ltd. Approves Executive Appointments

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.23 in 2Q 2022)

Byhealth Co., Ltd to Report First Half, 2023 Results on Aug 05, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to CN¥27.71

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.17 in 3Q 2021)

Consensus EPS estimates fall by 14%

Price target decreased to CN¥29.08

Second quarter 2022 earnings released

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

By-Health Co., Ltd. Implements Cash Dividend for 2021, Payable on 13 April 2022

By-Health Co., Ltd. Approves Cash Dividend for 2021

By-health Co., Ltd. Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to CN¥32.67

Price target decreased to CN¥33.98

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.32 in 3Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥36.49

Price target increased to CN¥34.07

First quarter 2021 earnings released: EPS CN¥0.52 (vs CN¥0.34 in 1Q 2020)

Investor sentiment improved over the past week

By-health Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day high: CN¥28.08

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.24 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Price target raised to CN¥31.56

New 90-day low: CN¥22.89

By-health Co., Ltd. to Report Fiscal Year 2020 Results on Mar 06, 2021

New 90-day high: CN¥25.87

Third quarter earnings released

By-health Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

By-health Co., Ltd. Announces Management Appointment

Price target raised to CN¥26.23

Price target raised to CN¥24.38

New 90-day high - CN¥22.58

By-health Co., Ltd. to Report First Half, 2020 Results on Jul 30, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven